Related Experiment Video
Updated: Oct 2, 2026

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018
Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent
Lorena Lazo de la Vega1, Daniel H Hovelson2, Andi K Cani1
1Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109.
Abstract:
Gene fusions between CIC and DUX4 define a rare class of soft tissue sarcomas poorly understood at the molecular level. Previous karyotyping and fluorescence in situ hybridization studies support chromosome 8 trisomy as a recurrent alteration; however, other driving alterations are largely unknown. Thus, we analyzed 11 formalin-fixed, paraffin-embedded CIC-DUX4 sarcoma tissue samples (including 3 sample pairs) using targeted Ion Torrent-based multiplexed polymerase chain reaction next-generation sequencing to characterize potential somatic driver alterations in 409 genes. Although we did not identify recurrent somatic mutations (point mutations or insertions/deletions), copy number analysis showed recurrent, broad copy number alterations, including gain of chromosome 8 and loss of 1p. In one sample pair (untreated primary and local recurrence resections), we identified similar copy number profiles and a somatic ARID1A R963X nonsense mutation exclusively in the local recurrence sample. In another sample pair (pre- and post-radiation treatment specimens), we observed single-copy loss of chromosome 7q exclusively in the posttreatment recurrence sample, supporting it as an acquired event after radiation treatment. In the last sample pair (near-concurrent, postchemotherapy primary and distant metastasis), molecular profiles were highly concordant, consistent with limited intertumoral heterogeneity. In summary, next-generation sequencing identified limited somatic driver mutations in CIC-DUX4 sarcomas. However, we identified novel, recurrent copy number alterations, including chromosome 1p, which is also the locus of ARID1A. Additional functional work and assessment of larger cohorts are needed to determine the biological and clinical significance of the alterations identified herein.
Insights
Next-generation sequencing revealed limited somatic mutations in CIC-DUX4 sarcomas. However, novel copy number alterations, including chromosome 1p loss, were identified, offering new insights into soft tissue sarcoma drivers.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- CIC-DUX4 sarcomas are rare soft tissue tumors with poorly understood molecular drivers.
- Recurrent alterations like chromosome 8 trisomy are known, but other genetic changes remain largely unidentified.
Purpose of the Study:
- To characterize potential somatic driver alterations in CIC-DUX4 sarcomas using next-generation sequencing.
- To identify novel genetic alterations beyond known chromosomal abnormalities.
Main Methods:
- Targeted next-generation sequencing of 409 genes in 11 CIC-DUX4 sarcoma samples.
- Analysis included copy number profiling and mutation detection.
- Comparison of matched primary and recurrence/metastasis samples.
Main Results:
- No recurrent somatic mutations (point mutations, indels) were found.
- Recurrent broad copy number alterations, including chromosome 8 gain and 1p loss, were identified.
- A somatic ARID1A nonsense mutation was found in a local recurrence sample; chromosome 7q loss was observed post-radiation.
Conclusions:
- Next-generation sequencing identified limited somatic driver mutations in CIC-DUX4 sarcomas.
- Novel recurrent copy number alterations, notably chromosome 1p loss (ARID1A locus), were discovered.
- Further research is needed to elucidate the biological and clinical impact of these findings.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
06:59Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter
Published on: March 31, 2022